Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed stage IV melanoma
• * Must have radiological evidence of lesions in liver (target or non-target)
• At least 1 measurable lesion outside previously irradiated field
• * At least 20 mm by contrast-enhanced CT scan, MRI, medical photography, or physical exam OR at least 10 mm by spiral CT scan
• No prior or concurrent clinical and/or objective evidence of brain metastasis
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• WHO 0-1
• Life expectancy:
• At least 3 months
• Hematopoietic:
• Hemoglobin at least 9.5 g/dL
• WBC at least 3,000/mm\^3
• Granulocyte count at least 2,000/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin no greater than 2 times upper limit of normal (ULN)
• AST and ALT no greater than 4 times ULN
• Alkaline phosphatase no greater than 4 times ULN
• Hepatitis B and C negative
• Renal:
• Creatinine no greater than 1.7 mg/dL
• Calcium no greater than 11.5 mg/dL
• Cardiovascular:
• No abnormal thallium stress test
• No acute myocardial infarction within the past year
• No New York Heart Association class III or IV heart disease
• Pulmonary:
• No asthma requiring active treatment within the past 5 years
• Oxygen saturation by pulse oximeter at least 90% unless FEV\_1 is greater than 2 L or at least 75% predicted
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• Concurrent medically-controlled (except with glyburide) or diet-controlled diabetes is allowed
• Concurrent medically-controlled thyroid dysfunction is allowed
• No other active malignancy within the past 5 years except carcinoma in situ of the cervix or localized squamous cell or basal cell skin cancer
• No serious non-malignant medical conditions, including psychiatric disability, that would preclude study compliance
• No active autoimmune disease (e.g., lupus, inflammatory bowel disease, or psoriasis)
• No active peptic and/or esophageal ulcer disease
• No hypersensitivity to histamine products or urticaria
• No active IV drug abuse
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No prior immunotherapy with high-dose IV interleukin-2 (IL-2)
• No prior combination immunotherapy with chemotherapy
• At least 1 year since prior low-dose adjuvant IL-2 as part of vaccine therapy or as therapy for stage II or III melanoma
• Chemotherapy:
• See Biologic therapy
• Endocrine therapy:
• No chronic systemic glucocorticoid steroids
• * Asthma inhalers, topical creams, or intra-articular injections allowed
• Hormonal therapy for non-melanoma-related conditions allowed
• Radiotherapy:
• See Disease Characteristics
• Concurrent radiotherapy as palliative therapy for isolated non-target lesions (e.g., bone lesions) allowed
• Surgery:
• Not specified
• Other:
• At least 4 weeks since prior therapy directed at malignancy
• At least 4 weeks since prior investigational medications or therapies
• At least 2 weeks since prior parenteral antioxidants and/or vitamins
• At least 2 weeks since prior antibiotics for active illness
• At least 2 weeks since prior H2 antagonists, beta-blockers, antihypertensives, antimalarials, antitrypanosomals, neuromuscular-blocking agents, tricyclic antidepressants, or alprazolam
• At least 24 hours since prior antihistamines
• No prior enrollment in any Maxim Pharmaceuticals investigational trials
• No concurrent anticonvulsant therapy for seizure disorder
• No other concurrent investigational drug
• No concurrent H2 antagonists, tricyclic antidepressants, alprazolam, beta- blockers, antihypertensives, antitrypanosomals, antimalarials, or monoamine oxidase inhibitors
• No concurrent inhibitors of diamine oxidase, monoamine oxidase, or histamine N-methyltransferase
• No concurrent antihistamines